Acute coronary syndromes (ACS) are caused by neoinclusive thrombosis of the coronary artery. Arterial atherothrombosis
usually results from a cracked atheroma plate and includes platelet and plasmatic component of
coagulation. The aim of pharmacological treatment is to influence activated platelets and plasma procoagulant
activity. Several clinical studies have demonstrated the benefits of antithrombotic treatment by acetylsalicylic acid,
clopidogrel and by blockers of platelet receptors IIb/IIIa. In ACS anticoagulant therapy the non-fractionated heparin
are replace ed by low-molecular heparins. The new standard in ACS therapy should become a combination of the
acetylsalicylic acid, enoxaparine and clopidogrel. Blockers of platelet receptors IIb/IIIa should be given namely to
patients indicated for the early invasive treatment.
acute coronary syndrome, pharmacotherapy.